Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.59 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4244106 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL7717314 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL4805985 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL115389 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL6551008 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL11429629 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL11351799 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3376831 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL7861837 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3166957 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4494707-A2 | OPHTHALMIC FORMULATION | University of Western Sydney (AU) | 2025-01-22 | — | — | EP | claimed |
| EP-3459929-A1 | OPHTHALMIC FORMULATION | University of Western Sydney (AU) | 2019-03-27 | — | — | EP | claimed |
| EP-2794550-B1 | OPHTHALMIC FORMULATION | UNIV OF WESTERN SYDNEY (AU) | 2019-02-20 | — | — | EP | claimed |
| CN-104271548-A | Ophthalmic formulation | UNIV WESTERN SYDNEY | 2015-01-07 | — | — | CN | claimed |
| US-20260049049-A1 | OPHTHALMIC FORMULATION | WESTERN SYDNEY UNIV (AU) | 2026-02-19 | — | — | US | disclosed |
| EP-4494707-A2 | OPHTHALMIC FORMULATION | University of Western Sydney (AU) | 2025-01-22 | — | — | EP | disclosed |
| US-20240368069-A1 | OPHTHALMIC FORMULATION | WESTERN SYDNEY UNIV (AU) | 2024-11-07 | — | — | US | disclosed |
| US-20210403410-A1 | OPHTHALMIC FORMULATION | WESTERN SYDNEY UNIV (AU) | 2021-12-30 | — | — | US | disclosed |
| US-20200190015-A1 | OPHTHALMIC FORMULATION | WESTERN SYDNEY UNIV (AU) | 2020-06-18 | — | — | US | disclosed |
| US-10385003-B2 | Ophthalmic formulation | MILLAR THOMAS (AU) | 2019-08-20 | — | — | US | disclosed |
| EP-3459929-A1 | OPHTHALMIC FORMULATION | University of Western Sydney (AU) | 2019-03-27 | — | — | EP | disclosed |
| EP-2794550-B1 | OPHTHALMIC FORMULATION | UNIV OF WESTERN SYDNEY (AU) | 2019-02-20 | — | — | EP | disclosed |
| CN-104271548-A | Ophthalmic formulation | UNIV WESTERN SYDNEY | 2015-01-07 | — | — | CN | disclosed |
| US-20140377335-A1 | OPHTHALMIC FORMULATION | UNIV WESTERN SYDNEY (AU) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190015-A1 | OPHTHALMIC FORMULATION | C9, C1R, F12 | CHRM1 470/4885AKR1A1 87/4885CHRM3 332/4885 |
| US-10385003-B2 | Ophthalmic formulation | C9, C1R, C1S | CHRM1 472/4885AKR1A1 111/4885CHRM3 379/4885 |
| US-20140377335-A1 | OPHTHALMIC FORMULATION | C9, C1R, C1S | CHRM1 472/4885AKR1A1 111/4885CHRM3 379/4885 |
| US-20210403410-A1 | OPHTHALMIC FORMULATION | C9, C1R, C5 | CHRM1 1171/4885AKR1A1 195/4885CHRM3 523/4885 |
| US-20260049049-A1 | OPHTHALMIC FORMULATION | HACD3, STARD3, SPTLC3 | CHRM1 1222/4885AKR1A1 1876/4885CHRM3 1307/4885 |
| US-20240368069-A1 | OPHTHALMIC FORMULATION | C9, C1R, F12 | CHRM1 470/4885AKR1A1 87/4885CHRM3 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.